Who
Joseph Eid
EVP, R&D; Chief Medical Office
Company insider
Files Form 4 as: EVP, R&D; Chief Medical Office, Geron; SVP,Head Glob. Medical Affairs, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 48
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $414K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Dec 2019
- Last trade
- 17 Feb 2026
- Last filed
- 19 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,220,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,220,000 at $0.00 | filing |
| 11 Nov 2024filed 12 Nov 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500,000 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,154 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —2,154 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $48K738 at $64.80 | filing |
| 10 May 2021filed 11 May 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Sold | $73K1,118 at $65.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —625 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —55 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $11K179 at $60.93 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —946 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —164 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $21K348 at $60.93 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —812 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —15 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $16K260 at $60.93 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —3,751 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —730 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $86K1,405 at $60.93 | filing |
| 10 Mar 2021filed 12 Mar 2021 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —625 at $0.00 | filing |
News
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in RevenueBMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?BMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 VolatilityBMY · fool.com · 22 Oct 2026
0 headlines in the last 90 days name Joseph Eid; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.